Compare Macy's Inc (M) vs TG Therapeutics Inc (TGTX) Price & Performance

Macy's (M) trades at $23.92, down 3.94% in the last session, with a bullish technical signal and recent earnings beats. The stock shows attractive valuation metrics including a P/E of 10.13 and P/S of 0.3, while maintaining positive cash flow generation. Recent institutional buying and analyst coverage indicate growing confidence in the company's turnaround strategy.

The outlook remains cautiously optimistic with a consensus price target of $24.83 offering 4% upside potential. Key risks include retail sector headwinds and competitive pressures, but strong institutional interest and improving fundamentals support the case for gradual recovery. The dividend payment scheduled for July provides additional shareholder return.

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.